Filing Flows › Comparisons › ROIV vs ATNM
Roivant Sciences vs Actinium Pharmaceuticals: ROIV and ATNM compared
Roivant Sciences is the larger company: $35.1M of revenue in its latest quarter (Q2 FY27) against $35.0M for Actinium Pharmaceuticals (Q2 2026). Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -763.2%.
Where the money goes: ROIV and ATNM
Roivant Sciences (ROIV) · Q2 FY27
Roivant Sciences, Q2 FY27: revenue $35.1M (22× year over year), operating margin -763.2%, net loss $137M, operating cash flow $594M. The chart follows the revenue to costs, profit and cash.
Actinium Pharmaceuticals (ATNM) · Q2 2026
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
| Roivant Sciences (ROIV) | Actinium Pharmaceuticals (ATNM) | |
|---|---|---|
| Latest quarter | Q2 FY27 | Q2 2026 |
| Revenue | $35.1M | $35.0M |
| Revenue growth, Y/Y | 22× | — |
| Operating margin | -763.2% | 78.8% |
| Net earnings | −$137M | $27.9M |
| Net margin | -390.7% | 79.7% |
| Operating cash flow | $594M | −$5.2M |
| Free cash flow | $594M | — |
Where the revenue comes from
Roivant Sciences
- Product revenue, net: $31.0M (88%)
- License, milestone and other revenue: $4.2M (12%)
Questions
Which is bigger, Roivant Sciences or Actinium Pharmaceuticals?
Roivant Sciences is the larger company: $35.1M of revenue in its latest quarter (Q2 FY27) against $35.0M for Actinium Pharmaceuticals (Q2 2026).
Is Roivant Sciences or Actinium Pharmaceuticals growing faster?
Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -763.2%.
More: Roivant Sciences earnings · how Roivant Sciences makes money · Actinium Pharmaceuticals earnings · how Actinium Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.